[O12] てんかん 2

[O12-1] Phase III, multicenter, open-label study of Nasal Diazepam in pediatric patients with or at risk for status epilepticus

^○Eiji Nakagawa¹, Jun Tooyama², Ryutaro Kira³, Mitsugu Uematsu⁴, Shin Okazaki⁵, Hideaki Shiraishi⁶, Kazuhiro Muramatsu⁷, Kazuya Itomi⁸, Junichi Onuma⁹, Shinichiro Takeuchi⁹, Kikuo Tsukahara⁹, Katsumi Imai¹⁰ (1.National Center of Neurology and Psychiatry, Tokyo, Japan, 2.Nishiniigata Chuo Hospital, Niigata, Japan, 3.Fukuoka Children's hospital, Fukuoka, Japan, 4.Tohoku University Hospital, Miyagi, Japan, 5.Osaka City General Hospital, Osaka, Japan, 6.Hokkaido University Hospital, Hokkaido, Japan, 7.Jichi Medical University, ,Tochigi, Japan, 8.Aichi Children's Health and Medical Center, Aichi, Japan, 9.Aculys Pharma Inc., Tokyo, Japan, 10.NHO Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan)